Agilent Technologies, Inc. ($A) provides solutions to life sciences and diagnostics markets, with a market cap of $41.6 billion. The stock slightly underperformed the market, gaining 9.3% YTD and 12.8% over the past year, compared to the S&P 500’s 14.5% 2025 gains. Agilent outpaced the Healthcare Select Sector SPDR Fund, with 10.4% YTD gains. Following better-than-expected Q3 results, Agilent’s stock surged 5.3% in one trading session. Analysts project an adjusted EPS of $5.58 for fiscal 2025. The consensus rating is a “Moderate Buy,” with a mean price target of $151.92 and a street-high target of $170.

Read more at Barchart: Do Wall Street Analysts Like Agilent Technologies Stock?